JP7007673B2 - 生合成デバイスの調製方法及び診断におけるそれらの使用 - Google Patents
生合成デバイスの調製方法及び診断におけるそれらの使用 Download PDFInfo
- Publication number
- JP7007673B2 JP7007673B2 JP2018553919A JP2018553919A JP7007673B2 JP 7007673 B2 JP7007673 B2 JP 7007673B2 JP 2018553919 A JP2018553919 A JP 2018553919A JP 2018553919 A JP2018553919 A JP 2018553919A JP 7007673 B2 JP7007673 B2 JP 7007673B2
- Authority
- JP
- Japan
- Prior art keywords
- biochemical
- synthetic
- encapsulated
- biosynthetic
- insulin resistance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001851 biosynthetic effect Effects 0.000 title claims description 46
- 238000003745 diagnosis Methods 0.000 title claims description 19
- 238000002360 preparation method Methods 0.000 title description 3
- 238000000034 method Methods 0.000 claims description 149
- 229940088598 enzyme Drugs 0.000 claims description 67
- 239000012528 membrane Substances 0.000 claims description 43
- 239000002207 metabolite Substances 0.000 claims description 42
- 238000004364 calculation method Methods 0.000 claims description 29
- 210000002700 urine Anatomy 0.000 claims description 28
- 206010022489 Insulin Resistance Diseases 0.000 claims description 27
- 238000000338 in vitro Methods 0.000 claims description 27
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 27
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 25
- 238000012545 processing Methods 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims description 22
- 238000005842 biochemical reaction Methods 0.000 claims description 21
- 230000035699 permeability Effects 0.000 claims description 12
- 239000011159 matrix material Substances 0.000 claims description 10
- 102100031126 6-phosphogluconolactonase Human genes 0.000 claims description 9
- 108010029731 6-phosphogluconolactonase Proteins 0.000 claims description 9
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 claims description 9
- 108010028658 Leucine Dehydrogenase Proteins 0.000 claims description 9
- 230000010354 integration Effects 0.000 claims description 7
- 108010015776 Glucose oxidase Proteins 0.000 claims description 6
- 239000004366 Glucose oxidase Substances 0.000 claims description 6
- 229940116332 glucose oxidase Drugs 0.000 claims description 6
- 235000019420 glucose oxidase Nutrition 0.000 claims description 6
- 239000013610 patient sample Substances 0.000 claims description 6
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 4
- 102000003992 Peroxidases Human genes 0.000 claims description 3
- 235000000760 Wasabia japonica Nutrition 0.000 claims description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims 2
- 241001293164 Eutrema japonicum Species 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 98
- 238000013461 design Methods 0.000 description 74
- 102000004190 Enzymes Human genes 0.000 description 55
- 108090000790 Enzymes Proteins 0.000 description 55
- 238000006243 chemical reaction Methods 0.000 description 44
- 238000004422 calculation algorithm Methods 0.000 description 40
- 238000005538 encapsulation Methods 0.000 description 40
- 239000000090 biomarker Substances 0.000 description 39
- 210000001874 anterior cell Anatomy 0.000 description 37
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 36
- 206010012601 diabetes mellitus Diseases 0.000 description 36
- 238000004519 manufacturing process Methods 0.000 description 35
- 230000008569 process Effects 0.000 description 35
- 230000015572 biosynthetic process Effects 0.000 description 33
- 238000004088 simulation Methods 0.000 description 33
- 238000013459 approach Methods 0.000 description 29
- 230000006399 behavior Effects 0.000 description 29
- 230000006870 function Effects 0.000 description 29
- 150000003904 phospholipids Chemical class 0.000 description 29
- 238000004458 analytical method Methods 0.000 description 28
- 238000000126 in silico method Methods 0.000 description 28
- 239000000839 emulsion Substances 0.000 description 27
- 230000000875 corresponding effect Effects 0.000 description 25
- 239000000243 solution Substances 0.000 description 24
- 241000894007 species Species 0.000 description 24
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 150000005693 branched-chain amino acids Chemical class 0.000 description 22
- 230000001575 pathological effect Effects 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 238000011156 evaluation Methods 0.000 description 20
- 239000000126 substance Substances 0.000 description 20
- 239000000872 buffer Substances 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 19
- 230000007246 mechanism Effects 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 201000010099 disease Diseases 0.000 description 18
- 239000002502 liposome Substances 0.000 description 18
- 239000000523 sample Substances 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 18
- 238000001514 detection method Methods 0.000 description 17
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 17
- 238000005259 measurement Methods 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 230000004044 response Effects 0.000 description 16
- 238000012795 verification Methods 0.000 description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- 239000008103 glucose Substances 0.000 description 15
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 15
- 230000002123 temporal effect Effects 0.000 description 15
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 14
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 14
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 14
- 239000005642 Oleic acid Substances 0.000 description 14
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 14
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 14
- 238000012512 characterization method Methods 0.000 description 13
- 238000009792 diffusion process Methods 0.000 description 13
- 150000002632 lipids Chemical class 0.000 description 13
- 239000003921 oil Substances 0.000 description 13
- 230000035945 sensitivity Effects 0.000 description 13
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 230000008901 benefit Effects 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000010276 construction Methods 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 230000002503 metabolic effect Effects 0.000 description 11
- 230000007170 pathology Effects 0.000 description 11
- 230000027756 respiratory electron transport chain Effects 0.000 description 11
- 229910001868 water Inorganic materials 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 10
- 230000001413 cellular effect Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 229950006238 nadide Drugs 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000007613 environmental effect Effects 0.000 description 9
- 239000004310 lactic acid Substances 0.000 description 9
- 235000014655 lactic acid Nutrition 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- 230000009471 action Effects 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 238000009739 binding Methods 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000005457 optimization Methods 0.000 description 8
- ZTOJFFHGPLIVKC-YAFCTCPESA-N (2e)-3-ethyl-2-[(z)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S\1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C/1=N/N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-YAFCTCPESA-N 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000012938 design process Methods 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- 238000013507 mapping Methods 0.000 description 7
- 238000010206 sensitivity analysis Methods 0.000 description 7
- 230000009897 systematic effect Effects 0.000 description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
- 101710092462 Alpha-hemolysin Proteins 0.000 description 6
- 239000000592 Artificial Cell Substances 0.000 description 6
- 239000000232 Lipid Bilayer Substances 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 238000004624 confocal microscopy Methods 0.000 description 6
- 239000004205 dimethyl polysiloxane Substances 0.000 description 6
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 238000001000 micrograph Methods 0.000 description 6
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 6
- 238000004987 plasma desorption mass spectroscopy Methods 0.000 description 6
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 6
- 229920000575 polymersome Polymers 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- -1 primary Chemical class 0.000 description 6
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 5
- 230000008827 biological function Effects 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 238000005094 computer simulation Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000012774 diagnostic algorithm Methods 0.000 description 5
- 238000003748 differential diagnosis Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 150000002576 ketones Chemical class 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 238000013432 robust analysis Methods 0.000 description 5
- 238000001338 self-assembly Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 4
- 208000002249 Diabetes Complications Diseases 0.000 description 4
- 108010006464 Hemolysin Proteins Proteins 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000011960 computer-aided design Methods 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 4
- 238000006073 displacement reaction Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000003228 hemolysin Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000000638 solvent extraction Methods 0.000 description 4
- 238000002948 stochastic simulation Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 238000012800 visualization Methods 0.000 description 4
- 238000009736 wetting Methods 0.000 description 4
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 3
- LTYUPYUWXRTNFQ-UHFFFAOYSA-N 5,6-diamino-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=C1C=C(N)C(N)=C2 LTYUPYUWXRTNFQ-UHFFFAOYSA-N 0.000 description 3
- 108010025188 Alcohol oxidase Proteins 0.000 description 3
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 3
- 206010012655 Diabetic complications Diseases 0.000 description 3
- YPZRHBJKEMOYQH-UYBVJOGSSA-L FADH2(2-) Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP([O-])(=O)OP([O-])(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C(NC(=O)NC2=O)=C2NC2=C1C=C(C)C(C)=C2 YPZRHBJKEMOYQH-UYBVJOGSSA-L 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 3
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 108700005078 Synthetic Genes Proteins 0.000 description 3
- 238000011481 absorbance measurement Methods 0.000 description 3
- 230000003044 adaptive effect Effects 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 238000009535 clinical urine test Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 150000001982 diacylglycerols Chemical class 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000003284 homeostatic effect Effects 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 208000006443 lactic acidosis Diseases 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 229920001993 poloxamer 188 Polymers 0.000 description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000006479 redox reaction Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- LJCNDNBULVLKSG-UHFFFAOYSA-N 2-aminoacetic acid;butane Chemical compound CCCC.CCCC.NCC(O)=O LJCNDNBULVLKSG-UHFFFAOYSA-N 0.000 description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 230000005653 Brownian motion process Effects 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010024882 Electron Transport Complex III Proteins 0.000 description 2
- 102000015782 Electron Transport Complex III Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010055870 Fatty Acid Transport Proteins Proteins 0.000 description 2
- 102000000476 Fatty Acid Transport Proteins Human genes 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000009433 Insulin Receptor Substrate Proteins Human genes 0.000 description 2
- 108010034219 Insulin Receptor Substrate Proteins Proteins 0.000 description 2
- 108010007843 NADH oxidase Proteins 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 101710135349 Venom phosphodiesterase Proteins 0.000 description 2
- 244000195452 Wasabia japonica Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000000429 assembly Methods 0.000 description 2
- 230000000712 assembly Effects 0.000 description 2
- 239000003012 bilayer membrane Substances 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 238000005537 brownian motion Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000000739 chaotic effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 238000000205 computational method Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000007435 diagnostic evaluation Methods 0.000 description 2
- 238000012631 diagnostic technique Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000002408 directed self-assembly Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000009652 hydrodynamic focusing Methods 0.000 description 2
- 230000010365 information processing Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004001 molecular interaction Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000005501 phase interface Effects 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000002702 ribosome display Methods 0.000 description 2
- RODXRVNMMDRFIK-UHFFFAOYSA-N scopoletin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2 RODXRVNMMDRFIK-UHFFFAOYSA-N 0.000 description 2
- 238000013515 script Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 230000005641 tunneling Effects 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 101710160335 2-Hydroxyacid oxidase 2 Proteins 0.000 description 1
- 102100038838 2-Hydroxyacid oxidase 2 Human genes 0.000 description 1
- ZTOJFFHGPLIVKC-UHFFFAOYSA-N 3-ethyl-2-[(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C1=NN=C1SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-UHFFFAOYSA-N 0.000 description 1
- DBXBTMSZEOQQDU-UHFFFAOYSA-N 3-hydroxyisobutyric acid Chemical compound OCC(C)C(O)=O DBXBTMSZEOQQDU-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 108091023020 Aldehyde Oxidase Proteins 0.000 description 1
- 102000048262 Aldehyde oxidases Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000995051 Brenda Species 0.000 description 1
- 229920000049 Carbon (fiber) Polymers 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108030002440 Catalase peroxidases Proteins 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- XEHFSYYAGCUKEN-UHFFFAOYSA-N Dihydroscopoletin Natural products C1CC(=O)OC2=C1C=C(OC)C(O)=C2 XEHFSYYAGCUKEN-UHFFFAOYSA-N 0.000 description 1
- 108091006149 Electron carriers Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023388 Ketonuria Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 108050006365 L-lactate oxidases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 108090000913 Nitrate Reductases Proteins 0.000 description 1
- 108090000334 Nitrate reductase (NAD(P)H) Proteins 0.000 description 1
- 108010025915 Nitrite Reductases Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010059332 Photosynthetic Reaction Center Complex Proteins Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 108030006554 Tryptophan dehydrogenases Proteins 0.000 description 1
- 241000722921 Tulipa gesneriana Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000002210 biocatalytic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000004917 carbon fiber Substances 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000003269 fluorescent indicator Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000008571 general function Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000003869 genetically modified organism Nutrition 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000008155 medical solution Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000009935 nitrosation Effects 0.000 description 1
- 238000007034 nitrosation reaction Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 108091008104 nucleic acid aptamers Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008723 osmotic stress Effects 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 230000008121 plant development Effects 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000006555 post-translational control Effects 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 238000005295 random walk Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- FWYIBGHGBOVPNL-UHFFFAOYSA-N scopoletin Natural products COC=1C=C2C=CC(OC2=C(C1)O)=O FWYIBGHGBOVPNL-UHFFFAOYSA-N 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012536 storage buffer Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000009889 stress physiology Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000009482 thermal adhesion granulation Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/5432—Liposomes or microcapsules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N3/00—Computing arrangements based on biological models
- G06N3/002—Biomolecular computers, i.e. using biomolecules, proteins, cells
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C99/00—Subject matter not provided for in other groups of this subclass
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Theoretical Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Mathematical Physics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Computing Systems (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Clinical Laboratory Science (AREA)
- Dispersion Chemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Data Mining & Analysis (AREA)
- Evolutionary Computation (AREA)
- Computational Linguistics (AREA)
- Artificial Intelligence (AREA)
- Software Systems (AREA)
- Bioinformatics & Computational Biology (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
Description
-微小環境内で空間的に閉じ込める(又は区画化される)又はカプセル化するステップ、
-少なくとも1つの生体分子要素であって、少なくとも1つの生体分子信号のバイオセンシングを達成するために生化学反応を支援し、感知された信号の多重化及び使用者定義の信号の処理/計算/論理操作への統合を達成するため更なる生化学的反応を支援する生体分子要素;
を含み、
前述のマイクロ/ナノスケール生合成デバイスは、前述の生体分子信号に対してプログラム可能な信号処理/計算操作を実行することが可能であり、
前述の分析する系又はそのサンプルの存在下で、前述のマイクロ/ナノスケール生合成デバイスは、複雑な生物学的マトリックスにおいて検出された生体分子パラメータに従って、分析する系及び生合成デバイスの存在に起因して、前述の埋め込まれた生化学反応から少なくとも1つの出力信号を生成でき、また前述の信号処理操作を実行することができ、
前述の少なくとも1つの出力信号は、分析する系の状態を示す方法を対象とする。
a)適切かつアクセス可能なデータベースにインシリコに記憶された前述の標準的な生体分子要素から選択することにより、使用者定義の生化学的操作を実行する適切な合成生化学反応回路の設計及び生化学的実装ステップ;
b)前述のインシリコ設計された生合成デバイスの感度分析、堅牢性分析等の数学的動的モデリング及び予測ステップ;
c)ステップa)で選択された、前述の少なくとも1つの生体分子要素を含む、合成膜、微小環境、又はモジュール内にカプセル化された少なくとも1つの前述の微小環境又はモジュールを生成するステップ;並びに
d)ステップc)において生成された前述の微小環境又はカプセル化されたモジュールを集合させることによって生合成装置を生成するステップ;
を含む。
e)分析することが望まれる任意の環境の病理/状態の疾患/分類に関して特性評価された既知の多数のサンプルを測定するステップ;及び
f)最適化されたバイオマーカーを生成するための既存の診断技術と比較して、対象となるアルゴリズムの性能を更に最適化するように、生体分子要素内及び間の論理関係の最適化、並びにこれらのステップの1つ以上を繰り返し行うステップ
を更に含む。
a)合成又は半合成の生体分子要素、あるいは好ましくはタンパク質、より好ましくは酵素、発現しない核酸、及び代謝産物からなる群から選択される、天然に存在する生物系から単離された要素であって、前述の生体分子要素又は要素は、選択透過性を有する合成、半合成、又は天然に存在する膜又はポリマー支持体内に空間的に閉じ込められ/区画化されている;
b)複雑な生物学的マトリックスにおいて少なくとも1つの生体分子信号のバイオセンシングを達成するための生化学的反応を支援する前述の生体分子又は単離された要素;
c)感知された信号の多重化及び使用者定義の信号の処理/計算/論理操作への統合を達成するため生化学的反応を支援する前記生体分子要素;
e)前記装置が、生体分子信号に対してプログラム可能な信号処理/計算操作を実行することが可能であること;
f)前記装置が、複雑な生物学的マトリックスにおいて検出された生体分子パラメータに従って、埋め込まれた生化学反応により少なくとも1つの可読/測定可能な物理化学的出力を生成でき、また信号処理操作を実行することができ、生物学的マトリックスポイントに関する情報を与えることができること;
を含む。
a)混合物を生成するために、本発明の方法によって得ることが可能若しくは得られるマイクロ/ナノスケール生合成デバイス、又は本発明で定義されるマイクロ/ナノスケール生合成デバイスを、前述の化合物を含有し易いサンプルと接触させるステップ;
b)少なくとも1つの生化学反応の実施に適合した条件で前述の混合物をインキュベートして、少なくとも前述の出力信号、好ましくは可読/測定可能な物理化学的出力信号を生成するステップ、ここで前述の出力信号は、前述のサンプルを分析するために望まれる前述の化合物の前述の存在及び/又は前述のレベルを示す;
c)ステップb)で生成された前述の出力信号を検出又は測定するステップ;及び
d)ステップc)において生成/測定された前述の信号、前述の化合物の前述の存在及び/又は前述のレベルを形成し、判定するステップを含む。
a)本発明の方法によって得ることが可能若しくは得られる1つの若しくは複数の生合成デバイス装置、又は本発明で定義されるマイクロ/ナノスケール生合成デバイスを得るステップ、ただし前述のデバイスは1つのタイプの区画、微小環境、モジュール、若しくは前細胞、又はその異なる種類を含み、(区画、微小環境、モジュール、若しくは前細胞又はデバイスの)分布が対象とする診断目的に関して予め最適化されている;
b)前述の生合成デバイスを患者サンプルと接触させるステップ;
c)各デバイスについてステップb)で生成された出力信号を検出又は測定するステップ、但し、ステップc)で生成/測定される前述の信号は、疾患の診断若しくは疾患のリスクの予測、又は前述の患者におけるヒトの病状の分類を示す、
を含む。
-酵素:グルコース-1-デヒドロゲナーゼ、グルコースオキシダーゼ、アルコールデヒドロゲナーゼ、ロイシンデヒドロゲナーゼ、硝酸レダクターゼ、乳酸オキシダーゼ、アルコールオキシダーゼ、西洋ワサビペルオキシダーゼ;及び
-代謝産物:レサズリン、NADH、NAD、ABTS、MTT(3-(4,5-ジメチルチアゾール-2-イル)-2,5-ジフェニルテトラゾリウムブロマイド)
から好ましくは選択される酵素又は代謝産物からなる群から選択される。
-酵素:ロイシンデヒドロゲナーゼ、及び任意に
-代謝産物:MTT、NADH、NAD
を含む。
a)カプセル化された生化学要素として、
-酵素:ロイシンデヒドロゲナーゼ;及び任意に
-代謝産物:MTT、NADH、NAD;
を含む第1のモジュール、並びに
b)カプセル化された生化学要素として
-酵素:グルコース-1-デヒドロゲナーゼ、又はグルコースオキシダーゼ、及び西洋わさびペルオキシダーゼ;及び任意に
-代謝産物:レサズリン
を含む第2のモジュール
という2つの異なるモジュールを実装する。
-酵素:グルコースオキシダーゼ又はグルコース1-デヒドロゲナーゼ、及びロイシンデヒドロゲナーゼの両方、及び任意に西洋ワサビペルオキシダーゼ(HRP);並びに任意に、
-代謝産物:レザスリン、NADH、NAD、及び任意にMTT;
を含む。
細胞内タンパク質染色、RNA検出、酵素免疫スポットアッセイ(ELISPOT)、蛍光定量法、蛍光染色、限界希釈アッセイを用いた定量、比色測定、指示物質、反応速度のパターン、濃度のパターン、ELISA及び類似のアッセイ、ハイスループットのゲノミクス及びプロテオミクス、分光法、又は当業者によって周知の他の信号である。
-酵素:ロイシンデヒドロゲナーゼ;及び任意に
-代謝産物:MTT、NADH、NAD、
を含む、小胞、リポソーム(非生物生合成デバイス)を含むが、これに限定されない少なくとも1つのモジュール、並びに任意に、
b)カプセル化された生化学要素として、
-酵素:グルコース-1-デヒドロゲナーゼ及び西洋わさびペルオキシダーゼ;並びに任意に
-代謝産物:レサズリン;
を含む第2のモジュールを含む。
-酵素:グルコースオキシダーゼ、又はグルコース1-デヒドロゲナーゼ、及びロイシンデヒドロゲナーゼの両方、及び任意に西洋ワサビペルオキシダーゼ(HRP);並びに任意に、
-代謝産物:レザスリンNADH、NAD、及び任意にMTT
を含む。
-酵素:グルコースオキシダーゼ、又はグルコース1-デヒドロゲナーゼ、及びロイシンデヒドロゲナーゼの両方、及び任意に西洋ワサビペルオキシダーゼ(HRP);並びに任意に、
-代謝産物:レザスリンNADH、NAD、及び任意にMTT;
を含む。
ケトン>17μM(10mg/dl、>0の場合、病理的)
グルコース>1.39mM(25mg/dl、病理閾値)
乳酸>10μM(>0の場合、病理的)
EtOH>17.4mM(80mg/dl、DIUに相当)
NOx>1000μM
図8~図11を参照
図13及び図14を参照
・1つのCmax-入力NORゲート
・Cmax2及び3入力ANDゲート。
・Vmaxインバータ前細胞
・2.Vmaxタイプの入力不要定数前細胞。各変数の2つの可能な値を表す定数の偽又は真を出力する。
・各定数の前細胞出力を適切なAND入力又はインバータにキャストするために、入力を2つ(又はそれより多く)の出力に複製する、配線している前細胞の数に依存する式。
1. Purnick, P. E. M. & Weiss, R. The second wave of synthetic biology: from modules to systems. Nat. Rev. Mol. Cell Biol. 10, 410-422 (2009).
2. Canton, B., Labno, A. & Endy, D. Refinement and standardization of synthetic biological parts and devices. Nat. Biotechnol. 26, 787-793 (2008).
3. Endy, D. Foundations for engineering biology. Nature 438, 449-453 (2005).
4. Smolke, C. D. Building outside of the box: iGEM and the BioBricks Foundation. Nat. Biotechnol. 27, 1099-1102 (2009).
5. Benenson, Y. Biomolecular computing systems: principles, progress and potential. Nat. Rev. Genet. 13, 455-468 (2012).
6. Courbet, A., Endy, D., Renard, E., Molina, F. & Bonnet, J. Detection of pathological biomarkers in human clinical samples via amplifying genetic switches and logic gates. Sci. Transl. Med. 7, 289ra83-289ra83 (2015).
7. Salis, H., Tamsir, A. & Voigt, C. Engineering bacterial signals and sensors. Contrib. Microbiol. 16, 194-225 (2009).
8. Raut, N., O’Connor, G., Pasini, P. & Daunert, S. Engineered cells as biosensing systems in biomedical analysis. Anal. Bioanal. Chem. 402, 3147-3159 (2012).
9. Wang, B., Barahona, M. & Buck, M. A modular cell-based biosensor using engineered genetic logic circuits to detect and integrate multiple environmental signals. Biosens. Bioelectron. 40, 368-376 (2013).
10. Su, L., Jia, W., Hou, C. & Lei, Y. Microbial biosensors: A review. Biosens. Bioelectron. 26, 1788-1799 (2011).
11. Rialle, S. et al. BioNetCAD: design, simulation and experimental validation of synthetic biochemical networks. Bioinformatics 26, 2298-2304 (2010).
12. Amar, P. et al. A stochastic automaton shows how enzyme assemblies may contribute to metabolic efficiency. BMC Syst. Biol. 2, 27 (2008).
13. Rizk, A., Batt, G., Fages, F. & Soliman, S. A general computational method for robustness analysis with applications to synthetic gene networks. Bioinformatics 25, i169-i178 (2009).
14. Noireaux, V. & Libchaber, A. A vesicle bioreactor as a step toward an artificial cell assembly. Proc. Natl. Acad. Sci. U. S. A. 101, 17669-17674 (2004).
15. Smaldon, J. et al. A computational study of liposome logic: towards cellular computing from the bottom up. Syst. Synth. Biol. 4, 157-179 (2010).
16. Elani, Y., Law, R. V. & Ces, O. Vesicle-based artificial cells as chemical microreactors with spatially segregated reaction pathways. Nat. Commun. 5, 5305 (2014).
17. Kamat, N. P., Katz, J. S. & Hammer, D. A. Engineering Polymersome Protocells. J. Phys. Chem. Lett. 2, 1612-1623 (2011).
18 Peters, R. J. R. W. et al. Cascade Reactions in Multicompartmentalized Polymersomes. Angew. Chem. Int. Ed. 53, 146-150 (2014).
19. Sarpeshkar, R. Ultra low power bioelectronics: fundamentals, biomedical applications, and bio-inspired systems. (Cambridge University Press, 2010).
20. Khalil, A. S. & Collins, J. J. Synthetic biology: applications come of age. Nat. Rev. Genet. 11, 367-379 (2010).
21. Archana Chugh, P. B. Synthetic Biology Based Biosensors and the Emerging Governance Issues. Curr. Synth. Syst. Biol. 01, (2013).
22. Shetty, R. P., Endy, D. & Knight, T. F. Engineering BioBrick vectors from BioBrick parts. J. Biol. Eng. 2, 5 (2008).
23. Breitling, R. & Takano, E. Synthetic biology advances for pharmaceutical production. Curr. Opin. Biotechnol. 35, 46-51 (2015).
24. Ye, H. & Fussenegger, M. Synthetic therapeutic gene circuits in mammalian cells. FEBS Lett. 588, 2537-2544 (2014).
25. Semenov, S. N. et al. Rational design of functional and tunable oscillating enzymatic networks. Nat. Chem. 7, 160-165 (2015).
26. Luisi, P. L. & Stano, P. The minimal cell the biophysics of cell compartment and the origin of cell functionality. (Springer, 2011). at <http://site.ebrary.com/id/10427796>
27. Protocells: bridging nonliving and living matter. (MIT Press, 2009).
28. Noireaux, V., Maeda, Y. T. & Libchaber, A. Development of an artificial cell, from self-organization to computation and self-reproduction. Proc. Natl. Acad. Sci. 108, 3473-3480 (2011).
29. Huang, X., Patil, A. J., Li, M. & Mann, S. Design and Construction of Higher-Order Structure and Function in Proteinosome-Based Protocells. J. Am. Chem. Soc. 136, 9225-9234 (2014).
30. Chandran, D., Bergmann, F. T., Sauro, H. M. & Densmore, D. in Design and Analysis of Biomolecular Circuits (eds. Koeppl, H., Setti, G., di Bernardo, M. & Densmore, D.) 203-224 (Springer New York, 2011). at <http://link.springer.com/10.1007/978-1-4419-6766-4_10>
31. Koeppl, H. Design and analysis of bio-molecular circuits. (Springer, 2011).
32. Shinar, G. & Feinberg, M. Structural Sources of Robustness in Biochemical Reaction Networks. Science 327, 1389-1391 (2010).
33. Marchisio, M. A. & Stelling, J. Computational design tools for synthetic biology. Curr. Opin. Biotechnol. 20, 479-485 (2009).
34. Mendes, P. et al. in Systems Biology (ed. Maly, I. V.) 500, 17-59 (Humana Press, 2009).
35. Matsuoka, Y., Funahashi, A., Ghosh, S. & Kitano, H. in Transcription Factor Regulatory Networks (eds. Miyamoto-Sato, E., Ohashi, H., Sasaki, H., Nishikawa, J. & Yanagawa, H.) 1164, 121-145 (Springer New York, 2014).
36. Kaznessis, Y. N. in Methods in Enzymology 498, 137-152 (Elsevier, 2011).
36. Chaouiya, C. et al. SBML qualitative models: a model representation format and infrastructure to foster interactions between qualitative modelling formalisms and tools. BMC Syst. Biol. 7, 135 (2013).
38. Zheng, Y. & Sriram, G. Mathematical Modeling: Bridging the Gap between Concept and Realization in Synthetic Biology. J. Biomed. Biotechnol. 2010, 1-16 (2010).
39. Kaznessis, Y. N. Models for synthetic biology. BMC Syst. Biol. 1, 47 (2007).
40. Lewis, D. D., Villarreal, F. D., Wu, F. & Tan, C. Synthetic Biology Outside the Cell: Linking Computational Tools to Cell-Free Systems. Front. Bioeng. Biotechnol. 2, (2014).
41. Amar, P. HSIM: a simulation programme to study large assemblies of proteins. J. Biol. Phys. Chem. 4, 79-84 (2002).
42. Amar, P. & Pauleve, L. HSIM: A Hybrid Stochastic Simulation System for Systems Biology. Electron. Notes Theor. Comput. Sci. 313, 3-21 (2015).
43. Calzone, L., Fages, F. & Soliman, S. BIOCHAM: an environment for modeling biological systems and formalizing experimental knowledge. Bioinforma. Oxf. Engl. 22, 1805-1807 (2006).
44. Gay, S., Soliman, S. & Fages, F. A graphical method for reducing and relating models in systems biology. Bioinformatics 26, i575-i581 (2010).
45. Bouffar, M., Molina, F. & Amar, P. Extracting logic gates from a metabolic network. in pp. 13 (2015).
46. Hansen, N. & Ostermeier, A. Completely derandomized self-adaptation in evolution strategies. Evol. Comput. 9, 159-195 (2001).
47. Beal, J. Signal-to-Noise Ratio Measures Efficacy of Biological Computing Devices and Circuits. Front. Bioeng. Biotechnol. 3, (2015).
48. Walde, P., Cosentino, K., Engel, H. & Stano, P. Giant Vesicles: Preparations and Applications. ChemBioChem 11, 848-865 (2010).
49. Reeves, J. P. & Dowben, R. M. Formation and properties of thin-walled phospholipid vesicles. J. Cell. Physiol. 73, 49-60 (1969).
50. Pautot, S., Frisken, B. J. & Weitz, D. A. Engineering asymmetric vesicles. Proc. Natl. Acad. Sci. 100, 10718-10721 (2003).
51. van Swaay, D. & deMello, A. Microfluidic methods for forming liposomes. Lab. Chip 13, 752 (2013).
52. Jahn, A., Vreeland, W. N., Gaitan, M. & Locascio, L. E. Controlled vesicle self-assembly in microfluidic channels with hydrodynamic focusing. J. Am. Chem. Soc. 126, 2674-2675 (2004).
53. Richmond, D. L. et al. Forming giant vesicles with controlled membrane composition, asymmetry, and contents. Proc. Natl. Acad. Sci. 108, 9431-9436 (2011).
54. Tan, Y.-C., Hettiarachchi, K., Siu, M., Pan, Y.-R. & Lee, A. P. Controlled microfluidic encapsulation of cells, proteins, and microbeads in lipid vesicles. J. Am. Chem. Soc. 128, 5656-5658 (2006).
55. Matosevic, S. & Paegel, B. M. Stepwise Synthesis of Giant Unilamellar Vesicles on a Microfluidic Assembly Line. J. Am. Chem. Soc. 133, 2798-2800 (2011).
56. Teh, S.-Y., Khnouf, R., Fan, H. & Lee, A. P. Stable, biocompatible lipid vesicle generation by solvent extraction-based droplet microfluidics. Biomicrofluidics 5, 044113 (2011).
57. Jahn, A. et al. Microfluidic Mixing and the Formation of Nanoscale Lipid Vesicles. ACS Nano 4, 2077-2087 (2010).
58. Mijajlovic, M., Wright, D., Zivkovic, V., Bi, J. X. & Biggs, M. J. Microfluidic hydrodynamic focusing based synthesis of POPC liposomes for model biological systems. Colloids Surf. B Biointerfaces 104, 276-281 (2013).
59. Jahn, A., Vreeland, W. N., DeVoe, D. L., Locascio, L. E. & Gaitan, M. Microfluidic directed formation of liposomes of controlled size. Langmuir ACS J. Surf. Colloids 23, 6289-6293 (2007).
60. Shum, H. C., Lee, D., Yoon, I., Kodger, T. & Weitz, D. A. Double Emulsion Templated Monodisperse Phospholipid Vesicles. Langmuir 24, 7651-7653 (2008).
61. Shum, H. C., Kim, J.-W. & Weitz, D. A. Microfluidic Fabrication of Monodisperse Biocompatible and Biodegradable Polymersomes with Controlled Permeability. J. Am. Chem. Soc. 130, 9543-9549 (2008).
62. Gunther, A. & Jensen, K. F. Multiphase microfluidics: from flow characteristics to chemical and materials synthesis. Lab. Chip 6, 1487-1503 (2006).
63. Utada, A. S. Monodisperse Double Emulsions Generated from a Microcapillary Device. Science 308, 537-541 (2005).
64. Kozlov, M., Quarmyne, M., Chen, W. & McCarthy, T. J. Adsorption of Poly(vinyl alcohol) onto Hydrophobic Substrates. A General Approach for Hydrophilizing and Chemically Activating Surfaces. Macromolecules 36, 6054-6059 (2003).
65. Liposomes as tools in basic research and industry. (CRC Press, 1995).
66. Williams, M. S., Longmuir, K. J. & Yager, P. A practical guide to the staggered herringbone mixer. Lab. Chip 8, 1121 (2008).
67. Gullapalli, R. R., Demirel, M. C. & Butler, P. J. Molecular dynamics simulations of DiI-C18(3) in a DPPC lipid bilayer. Phys. Chem. Chem. Phys. 10, 3548 (2008).
68. Nagle JF & Tristram-Nagle S. Structure of lipid bilayers. Biochim Biophys Acta. 159-95. (2000).
69. Planchet, E. & Kaiser, W. M. Nitric oxide (NO) detection by DAF fluorescence and chemiluminescence: a comparison using abiotic and biotic NO sources. J. Exp. Bot. 57, 3043-3055 (2006).
70. Dean, J. V. & Harper, J. E. The Conversion of Nitrite to Nitrogen Oxide(s) by the Constitutive NAD(P)H-Nitrate Reductase Enzyme from Soybean. Plant Physiol. 88, 389-395 (1988).
71. Yokota, K. & Yamazaki, I. Analysis and computer simulation of aerobic oxidation of reduced nicotinamide adenine dinucleotide catalyzed by horseradish peroxidase. Biochemistry (Mosc.) 16, 1913-1920 (1977).
72. Singh, R. et al. Catalase-peroxidases (KatG) exhibit NADH oxidase activity. J. Biol. Chem. 279, 43098-43106 (2004).
73. Afanasyeva, M. S., Taraban, M. B., Purtov, P. A., Leshina, T. V. & Grissom, C. B. Magnetic spin effects in enzymatic reactions: radical oxidation of NADH by horseradish peroxidase. J. Am. Chem. Soc. 128, 8651-8658 (2006).
74. Yorita, K. et al. Conversion of L-lactate oxidase to a long chain alpha-hydroxyacid oxidase by site-directed mutagenesis of alanine 95 to glycine. J. Biol. Chem. 271, 28300-28305 (1996).
75. Liu, X. et al. Application of carbon fiber composite minielectrodes for measurement of kinetic constants of nitric oxide decay in solution. Nitric Oxide 23, 311-318 (2010).
76. Li, H., Kundu, T. K. & Zweier, J. L. Characterization of the Magnitude and Mechanism of Aldehyde Oxidase-mediated Nitric Oxide Production from Nitrite. J. Biol. Chem. 284, 33850-33858 (2009).
77. Kojima, H. et al. Detection and imaging of nitric oxide with novel fluorescent indicators: diaminofluoresceins. Anal. Chem. 70, 2446-2453 (1998).
78. Espey, M. G., Miranda, K. M., Thomas, D. D. & Wink, D. A. Distinction between nitrosating mechanisms within human cells and aqueous solution. J. Biol. Chem. 276, 30085-30091 (2001).
79. Arita, N. O., Cohen, M. F., Tokuda, G. & Yamasaki, H. in Nitric Oxide in Plant Growth, Development and Stress Physiology (eds. Lamattina, L. & Polacco, J. C.) 5, 269-280 (Springer Berlin Heidelberg, 2007).
80. E.F. Olasehinde & et al. Reaction Kinetics for Nitrosation of DAF-2 in Air Saturated Nitric Oxide Solution. Nature & Science p129 (2012).
81. Chaize, B., Colletier, J.-P., Winterhalter, M. & Fournier, D. Encapsulation of enzymes in liposomes: high encapsulation efficiency and control of substrate permeability. Artif. Cells. Blood Substit. Immobil. Biotechnol. 32, 67-75 (2004).
82. Yoshimoto, M. in Enzyme Stabilization and Immobilization (ed. Minteer, S. D.) 679, 9-18 (Humana Press, 2011).
83. Sunami, T., Hosoda, K., Suzuki, H., Matsuura, T. & Yomo, T. Cellular Compartment Model for Exploring the Effect of the Lipidic Membrane on the Kinetics of Encapsulated Biochemical Reactions. Langmuir 26, 8544-8551 (2010).
84. Thiele, J. et al. Fabrication of Polymersomes using Double-Emulsion Templates in Glass-Coated Stamped Microfluidic Devices. Small 6, 1723-1727 (2010).
85. Duncanson, W. J. et al. Microfluidic synthesis of advanced microparticles for encapsulation and controlled release. Lab. Chip 12, 2135 (2012).
86. Stanish, I. & Singh, A. Highly stable vesicles composed of a new chain-terminus acetylenic photopolymeric phospholipid. Chem. Phys. Lipids 112, 99-108 (2001).
87. Osyczka, A., Moser, C. C., Daldal, F. & Dutton, P. L. Reversible redox energy coupling in electron transfer chains. Nature 427, 607-612 (2004).
88. Katzen, F., Deshmukh, M., Daldal, F. & Beckwith, J. Evolutionary domain fusion expanded the substrate specificity of the transmembrane electron transporter DsbD. EMBO J. 21, 3960-3969 (2002).
89. Page, C. C., Moser, C. C., Chen, X. & Dutton, P. L. Natural engineering principles of electron tunnelling in biological oxidation-reduction. Nature 402, 47-52 (1999).
90. Wakeham, M. C. & Jones, M. R. Rewiring photosynthesis: engineering wrong-way electron transfer in the purple bacterial reaction centre. Biochem. Soc. Trans. 33, 851-857 (2005).
91. Hermann, T. & Patel, D. J. Adaptive recognition by nucleic acid aptamers. Science 287, 820-825 (2000).
92. Smuc, T., Ahn, I.-Y. & Ulrich, H. Nucleic acid aptamers as high affinity ligands in biotechnology and biosensorics. J. Pharm. Biomed. Anal. 81-82, 210-217 (2013).
93. Falciani, C., Lozzi, L., Pini, A. & Bracci, L. Bioactive peptides from libraries. Chem. Biol. 12, 417-426 (2005).
94. Stoltenburg, R., Reinemann, C. & Strehlitz, B. SELEX--a (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol. Eng. 24, 381-403 (2007).
95. Hanes, J., Schaffitzel, C., Knappik, A. & Pluckthun, A. Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display. Nat. Biotechnol. 18, 1287-1292 (2000).
96. Binz, H. K., Amstutz, P. & Pluckthun, A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat. Biotechnol. 23, 1257-1268 (2005).
97. Song, S., Kole, S. & Bernier, M. A chemical cross-linking method for the analysis of binding partners of heat shock protein-90 in intact cells. BioTechniques (2012). doi:10.2144/000113856
98. Xiang, Z. et al. Proximity-Enabled Protein Crosslinking through Genetically Encoding Haloalkane Unnatural Amino Acids. Angew. Chem. Int. Ed. 53, 2190-2193 (2014).
99. Strickland, D. et al. TULIPs: tunable, light-controlled interacting protein tags for cell biology. Nat. Methods 9, 379-384 (2012).
100. Rakhit, R., Navarro, R. & Wandless, T. J. Chemical biology strategies for posttranslational control of protein function. Chem. Biol. 21, 1238-1252 (2014).
101. Riggsbee, C. W. & Deiters, A. Recent advances in the photochemical control of protein function. Trends Biotechnol. 28, 468-475 (2010).
102. Watanabe, R. et al. Arrayed lipid bilayer chambers allow single-molecule analysis of membrane transporter activity. Nat. Commun. 5, (2014).
103. Stillwell, W. An introduction to biological membranes: from bilayers to rafts. (Elsevier/Academic Press, 2013).
104. Karp, R. M. in Complexity of Computer Computations (eds. Miller, R. E., Thatcher, J. W. & Bohlinger, J. D.) 85-103 (Springer US, 1972). at http://link.springer.com/10.1007/978-1-4684-2001-2_9
105. Wang, T.J. et al. Metabolite profiles and the risk of developing diabetes. Nature Medicine 17 (4) 448-454 (2011)
106. Jang, C. et al. A branched-chain amino acid metabolite drives vascular fatty acid transport and causes insulin-resistance. Nature Medicine 22 (4) 421-426 (2016)
107. Newgard, C.B. Interplay between Lipids and Branched-Chain Amino Acids in Development of Insulin Resistance. Cell Metabolism 15 606-614 (2012)
Claims (5)
- 生物学的サンプルから、患者におけるインスリン抵抗性又は初期インスリン抵抗性を診断するためにインビトロで使用するための、マイクロ/ナノスケールの生合成デバイスであって、前記生合成デバイスは、
a)組み立てられた微小環境又はカプセル化されたモジュールを含み、ここで、前記微小環境又はモジュールは、選択透過性を有する合成、半合成、若しくは天然に存在する膜又はポリマー支持体内に封入され、且つ天然に存在する生物系から単離された生化学要素を少なくとも含み;
前記生化学要素が、複雑な生物学的マトリックスにおいて少なくとも1つの生体分子信号のバイオセンシングを達成するための生化学的反応を支援し、
前記生化学要素が、感知された信号の多重化及び使用者定義の信号の処理/計算/論理操作への統合を達成するため生化学的反応を支援し、
前記デバイスが、生体分子信号に対してプログラム可能な信号処理/計算操作を実行することが可能であり、並びに、
前記デバイスが、複雑な生物学的マトリックスにおいて検出された生体分子信号に従って、埋め込まれた生化学反応により少なくとも1つの可読/測定可能な物理化学的出力信号を生成でき、また信号処理操作を実行することができ、また前記生物学的マトリックスに関する情報を与えることができ、
前記微小環境又はモジュールが、カプセル化された生化学要素として、
-酵素:ロイシンデヒドロゲナーゼ、及び任意に
-代謝産物:MTT、NADH、NAD
を含む、生物学的サンプルから患者におけるインスリン抵抗性又は初期インスリン抵抗性の診断のために、インビトロで使用するための、マイクロ/ナノスケールの生合成デバイス。 - 前記デバイスが
a)カプセル化された生化学要素として、
-酵素:ロイシンデヒドロゲナーゼ、及び任意に
-代謝産物:MTT、NADH、NAD
を含む第1のモジュール、並びに
b)カプセル化された生化学要素として
-酵素:グルコース-1-デヒドロゲナーゼ、又はグルコースオキシダーゼ、及び西洋わさびペルオキシダーゼ、並びに任意に
-代謝産物:レサズリン
を含む第2のモジュール
という2つの異なるモジュールを実装する、請求項1に記載のマイクロ/ナノスケールの生合成デバイス。 - 請求項1又は2に記載の少なくとも1つのデバイスを含む、キット。
- a)1若しくは複数の請求項1~3のいずれか1項に記載の生合成デバイス又はキットを得るステップ;
b)前記デバイスを患者サンプルと接触させることにより、出力信号を生成するステップ;
c)各デバイスについてステップb)で生成された前記出力信号を検出又は測定するステップ、但し、ステップc)で生成/測定される前記信号は、インスリン抵抗性又は初期インスリン抵抗性疾患のリスクの診断又は予測を示す;
を含む、患者におけるインスリン抵抗性又は初期インスリン抵抗性疾患を示すリスクの予測又は診断のためのインビトロでの方法。 - 試験される前記患者サンプルが、患者からの尿、血清、血漿、及び血液サンプルからなる群から選択される、請求項4に記載のインビトロ方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16165189.8 | 2016-04-13 | ||
EP16165189 | 2016-04-13 | ||
PCT/IB2017/000683 WO2017178896A2 (en) | 2016-04-13 | 2017-04-13 | Method for the preparation of biosynthetic device and their uses in diagnostics |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019520792A JP2019520792A (ja) | 2019-07-25 |
JP7007673B2 true JP7007673B2 (ja) | 2022-01-25 |
Family
ID=56024084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018553919A Active JP7007673B2 (ja) | 2016-04-13 | 2017-04-13 | 生合成デバイスの調製方法及び診断におけるそれらの使用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20190111422A1 (ja) |
JP (1) | JP7007673B2 (ja) |
CN (1) | CN109074422B (ja) |
BR (1) | BR112018070937A2 (ja) |
CA (1) | CA3020221C (ja) |
IL (1) | IL262203B1 (ja) |
WO (1) | WO2017178896A2 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11455567B2 (en) * | 2018-09-11 | 2022-09-27 | International Business Machines Corporation | Rules engine for social learning |
EP3899012A1 (en) * | 2018-12-20 | 2021-10-27 | Skillcell | Biodegradable biochemical sensor for determining the presence and/or the level of pesticides or endocrine disruptors: method and composition |
US20210333214A1 (en) * | 2020-03-31 | 2021-10-28 | Logicink Corporation | System for detection of a target analyte via self-testing, object surfaces, and the environment |
WO2023233017A1 (en) * | 2022-06-02 | 2023-12-07 | Skillcell | Urinary branched-chain amino acids (ubcaas) as insulin resistance biomarkers |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103951803A (zh) | 2014-05-05 | 2014-07-30 | 中国科学技术大学 | 一种制备灵敏响应聚合物囊泡的通用方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006122191A2 (en) * | 2005-05-10 | 2006-11-16 | The Uab Research Foundation | Improved method for determining crystalization parameters and apparatus for use with same |
US20120077184A1 (en) * | 2010-09-28 | 2012-03-29 | Starkdx Incorporated | Electromagnetic multiplex assay biosensor |
US9239903B2 (en) * | 2012-03-13 | 2016-01-19 | Gabriele Scheler | Determination of output of biochemical reaction networks |
SG11201505579TA (en) * | 2013-01-17 | 2015-08-28 | Univ California | Rapid identification of optimized combinations of input parameters for a complex system |
KR102344774B1 (ko) * | 2013-07-29 | 2021-12-28 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 자극을 동적으로 변화시키는 실-시간 피드백 시스템 제어 기술 플랫폼 |
US10653749B2 (en) * | 2015-04-16 | 2020-05-19 | The Regents Of The University Of California | Targeting GIV-GEF-GI signaling for treating diverse diseases |
-
2017
- 2017-04-13 CA CA3020221A patent/CA3020221C/en active Active
- 2017-04-13 CN CN201780027437.6A patent/CN109074422B/zh active Active
- 2017-04-13 US US16/090,291 patent/US20190111422A1/en active Pending
- 2017-04-13 JP JP2018553919A patent/JP7007673B2/ja active Active
- 2017-04-13 IL IL262203A patent/IL262203B1/en unknown
- 2017-04-13 BR BR112018070937A patent/BR112018070937A2/pt unknown
- 2017-04-13 WO PCT/IB2017/000683 patent/WO2017178896A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103951803A (zh) | 2014-05-05 | 2014-07-30 | 中国科学技术大学 | 一种制备灵敏响应聚合物囊泡的通用方法 |
Non-Patent Citations (2)
Title |
---|
Acta Biotheor, 2015, vol.63, pp.309-323 |
S. Ayukawa, et al.,RTRACS: A Modularized RNA-Dependent RNA Transcription System with High Programmability,Accounts of Chemical Research,2011年,vol. 44, no. 12,pp. 1369-1379 |
Also Published As
Publication number | Publication date |
---|---|
CN109074422A (zh) | 2018-12-21 |
CA3020221A1 (en) | 2017-10-19 |
WO2017178896A2 (en) | 2017-10-19 |
CN109074422B (zh) | 2022-05-13 |
JP2019520792A (ja) | 2019-07-25 |
IL262203A (en) | 2018-11-29 |
CA3020221C (en) | 2024-04-16 |
WO2017178896A3 (en) | 2018-07-19 |
BR112018070937A2 (pt) | 2019-01-29 |
IL262203B1 (en) | 2024-02-01 |
US20190111422A1 (en) | 2019-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7007673B2 (ja) | 生合成デバイスの調製方法及び診断におけるそれらの使用 | |
Van Meervelt et al. | Real-time conformational changes and controlled orientation of native proteins inside a protein nanoreactor | |
Sprague et al. | FRAP analysis of binding: proper and fitting | |
Willems et al. | Engineering and modeling the electrophoretic trapping of a single protein inside a nanopore | |
Courbet et al. | Computer‐aided biochemical programming of synthetic microreactors as diagnostic devices | |
Kastrup et al. | Modular chemical mechanism predicts spatiotemporal dynamics of initiation in the complex network of hemostasis | |
Muller et al. | A predictive model for yeast cell polarization in pheromone gradients | |
Banwarth-Kuhn et al. | How and why to build a mathematical model: A case study using prion aggregation | |
Blobel | Translational medicine meets new technologies for enabling personalized care | |
Lakin et al. | Domain-specific programming languages for computational nucleic acid systems | |
Le et al. | Computational modeling and prediction of the complex time-dependent phase behavior of lyotropic liquid crystals under in meso crystallization conditions | |
Moorthy et al. | Microfluidic based platform for characterization of protein interactions in hydrogel nanoenvironments | |
Teja et al. | Role of Artificial Neural Networks in Pharmaceutical Sciences. | |
Kawatsu et al. | Worm model for electron tunneling in proteins: Consolidation of the pathway model and the Dutton plot | |
Razavi et al. | Cellular signaling circuits interfaced with synthetic, post-translational, negating Boolean logic devices | |
Anikeeva et al. | Voices in methods development | |
EP3443495A2 (en) | Method for the preparation of biosynthetic device and their uses in diagnostics | |
Saurabh et al. | Modeling non-additive effects in neighboring chemically identical fluorophores | |
Janitra et al. | Multilayer Model of Gold Nanoparticles (AuNPs) and Its Application in the Classical Molecular Dynamics Simulation of Citrate-Capped AuNPs | |
Krasecki et al. | The Role of Experimental Noise in a Hybrid Classical-Molecular Computer to Solve Combinatorial Optimization Problems | |
Santos Schneider et al. | Biomachines for medical diagnosis | |
Cheong et al. | The macroscopic limit to synchronization of cellular clocks in single cells of Neurospora crassa | |
Bovyn et al. | Roles of motor on-rate and cargo mobility in intracellular transport | |
Li et al. | Models of single-molecule experiments with periodic perturbations reveal hidden dynamics in RNA folding | |
Shahzad et al. | Fluorescence correlation spectroscopy (FCS): a promising tool for biological research |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200221 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201023 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201104 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210201 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210324 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210430 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210713 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211011 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211124 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211223 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7007673 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |